Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2

Inclusion Criteria: * ¥ Age-18-65 * Stable ART for at least 12 months. * Screening plasma HIV RNA levels below level of quantification (\<40 to \<50 copies RNA/mL depending on the assay) for ≥ 6 months (a total of 3 measurements above the level of detection but \< 500 copies/ml will be allowed if each detectable measure is separated by at least 1 year) * Screening CD4 count ≥500 cells/µl * Laboratory tests (CBCD, CMP, Mg, Phosphorus, PT/PTT, TSH/T4,) performed within 14 days of study enrollment. All laboratory results (unless otherwise specified) must be Grade 1 or normal based on the DAIDS Adverse Event Grading Scale (Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events v2.0) * Adequate kidney function defined by estimated GFR (CrCl) \> 60 ml/min or ml/min/1.73 m2 (≤ grade 2 per DAIDS) and creatinine ≤ 1.5 x ULN * Adequate pulmonary function without any clinical signs or symptoms of severe pulmonary dysfunction. PFT testing must show FEV1 and DLCOcorr \> 50% of predicted if subjects have symptomatic or prior known impairment. * Transthoracic echocardiogram with PA pressures in the range of 18-26 mmHg * Ability to be off prednisone and other immunosuppressive drugs for at least 14 days before infusion of cells * Women of child bearing potential and men with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy * Voluntary written consent provided by the subject Exclusion Criteria: * Any condition that precludes lymph node biopsy or colonoscopy with biopsy * Active infection other than HIV currently requiring systemic antimicrobial therapy * History of deep vein thrombosis * Active significant, tissue invasive fungal infection requiring systemic antifungal therapy (dermatologic conditions requiring only topical therapy are allowed). * Chronic active hepatitis B or C (defined as antibody positive and DNA+ or HepBsAG+). * Breastfeeding * Intended modification of antiretroviral therapy in the next 24 weeks * NYHA (New York Heart Association) Class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction * Symptomatic congestive heart failure, unstable angina pectoris, or Myocardial infarction within 6 months prior to screening * Marked baseline prolongation of QT/QTc interval (e.g. demonstration of a QTc interval greater than 500 milliseconds) * On-going chronic systemic corticosteroid use or other immunosuppressive therapy (a history of mild asthma not requiring therapy is eligible and inhaled corticosteroids is allowed. Topical steroids are allowed.) * Psychiatric illness/social situations that would limit compliance with study requirements * Previous diagnosis of an autoimmune disease (e.g. rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, vasculitis) * Use of any anticoagulants within the previous 4 weeks. * Other illness that in the opinion of the investigator would exclude the patient from participating in this study